Viking Therapeutics has delivered a very large 5 year return, yet its current checks lean expensive, which raises questions about how much of the obesity drug opportunity is already reflected in the stock price.

• Viking Therapeutics has returned about 6x over 5 years, which puts extra focus on whether recent gains leave limited room for disappointment.
• The launch of the Phase 1 trial for obesity candidate VK3019 can support expectations for a broader weight loss pipeline. At the same time, clinical and regulatory setbacks across this portfolio remain a central risk to any valuation built on future treatments.
• The company screens as expensive on Simply Wall St’s broader checks, with 0 of 6 valuation metrics suggesting it is a clear bargain.

The issue now is whether Viking Therapeutics’ recent share price strength is justified by its long term earnings and cash flow potential, or if expectations have moved too far ahead of the fundamentals.

Does Viking Therapeutics Look Pricey on Book Value?

For a loss making biotech like Viking Therapeutics, the P/B ratio is often used as a quick way to see how heavily the market values its research pipeline and balance sheet.

Viking Therapeutics trades at a P/B of about 9.7x, compared with an industry average of roughly 2.8x and a peer group average near 5.6x. As a result, the stock sits on a sizeable premium to both broader biotechs and closer comparables. This gap indicates that investors are currently paying a higher price for Viking Therapeutics’ obesity and metabolic programs, including the recently highlighted VK2735 and VK3019 candidates, even though the company is still working through clinical and regulatory milestones.

Despite the recent focus on new obesity drug trials, the current P/B multiple places Viking Therapeutics at a valuation level that is high relative to sector norms.

On this P/B yardstick, Viking Therapeutics stock appears clearly overvalued compared with its biotech peers.

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Viking Therapeutics leaves off by making clear which future growth, margin and earnings assumptions would need to hold for the stock to be worth materially more or less than today’s price. They sit on Simply Wall St’s Community page as scenario-style views. Rather than focusing on a single multiple or output, each one lays out the assumptions behind its fair value so you can weigh them against actual results as they emerge.

One of the top community narratives on Viking Therapeutics: 66% undervalued

"The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path that may diversify future revenue sources and create operating leverage if both oral and injectable share the same active molecule..."

Do you think there's more to the story for Viking Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Viking Therapeutics currently screens as overvalued on traditional market multiples, with a P/B ratio well above both the broader biotech group and closer peers. That premium rests on confidence that its obesity and metabolic pipeline, including VK2735 and VK3019, can eventually justify a richer valuation than other loss making biotechs. For you, the key question is whether the current price already bakes in much of that potential, or if the science, trial outcomes and regulatory progress can still surprise positively enough to support today’s elevated expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.